Neisseria gonorrhoeae LOS Specific Neutra™ Antibody Products

Are you struggling with rising antibiotic resistance in Neisseria gonorrhoeae infections or the limitations of conventional therapies? Creative Biolabs' N. gonorrhoeae LOS specific Neutra™ antibody products overcome these challenges by leveraging proprietary hybridoma technology and epitope-specific validation, enabling rapid development of high-affinity antibodies to neutralize infections and combat multidrug-resistant strains.

Introduction to N. gonorrhoeae LOS

Neisseria gonorrhoeae Lipooligosaccharide (LOS) is a critical virulence factor in gonococcal infections. As a glycolipid embedded in the outer membrane, it facilitates bacterial adhesion, immune evasion, and systemic inflammation. Understanding its structural and functional complexity is pivotal for developing targeted interventions against this globally prevalent pathogen.

• Basic Information

N. gonorrhoeae LOS consists of a lipid A anchor, a core oligosaccharide, and variable terminal glycans. Unlike lipopolysaccharides in other Gram-negative bacteria, LOS lacks the O-antigen polysaccharide chain, making it smaller yet highly immunogenic. Its expression is modulated during infection to evade host defenses, contributing to persistent colonization and antibiotic resistance.

• Structure

LOS is composed of three domains:

- Lipid A: Activates host Toll-like receptor 4 (TLR4), triggering pro-inflammatory cytokine release.

- Core oligosaccharide: Contains heptose and glucose residues critical for membrane stability.

- Variable terminal extensions: Include lactose or sialic acid moieties that mimic host antigens, enabling immune mimicry. Structural variations in these extensions correlate with strain-specific virulence and tissue tropism.

Fig.1 Gonococcal LOS structure.¹

• Related Signaling Pathways

LOS activates multiple host pathways:

- TLR4/NF-κB: Drives inflammation and tissue damage during infection.

- Complement system: LOS sialylation inhibits complement-mediated lysis, enhancing bacterial survival.

- Apoptosis pathways: Prolonged LOS exposure induces epithelial cell death, facilitating bacterial dissemination.

Fig.2 LOS sialylation and complement resistance.¹

• Related Diseases

N. gonorrhoeae causes gonorrhea, a sexually transmitted infection with complications such as pelvic inflammatory disease, infertility, and disseminated gonococcal infection. Alarmingly, multidrug-resistant strains are surging globally, rendering first-line antibiotics less effective. This underscores the urgency for alternative therapies targeting LOS, a conserved virulence factor.

Applications of N. gonorrhoeae LOS Neutralizing Antibodies

• Diagnostic Development

LOS-specific antibodies enable rapid detection of gonococcal infections in clinical specimens. Their high specificity distinguishes N. gonorrhoeae from commensal Neisseria species, improving diagnostic accuracy in low-resource settings.

• Therapeutic Intervention

Neutralizing antibodies block LOS-mediated TLR4 activation, reducing inflammation and tissue damage. In murine models, passive immunization with anti-LOS antibodies significantly decreased bacterial colonization in mucosal tissues, highlighting their potential as adjuncts or alternatives to antibiotics.

• Vaccine Research

Anti-LOS antibodies serve as benchmarks for vaccine efficacy. By measuring antibody-mediated complement killing or opsonophagocytosis, researchers can evaluate candidate vaccines targeting LOS in preclinical trials.

• Antimicrobial Resistance Surveillance

Antibodies specific to LOS variants associated with antibiotic resistance (e.g., altered lipid A structures) help track emerging resistant strains, informing public health responses.

Our Anti-N. gonorrhoeae LOS Antibodies

Neutralizing antibodies targeting LOS disrupt bacterial adhesion, prevent immune evasion, and enhance complement-mediated killing. Key advantages include:

- Epitope specificity: Antibodies bind to conserved regions of lipid A or the core oligosaccharide, bypassing strain variability.

- Functional validation: Demonstrated in vitro and in vivo models to reduce bacterial load and inflammation.

- Therapeutic synergy: Enhance efficacy of remaining antibiotics by sensitizing resistant strains.

Creative Biolabs' antibodies are validated for use in ELISA, flow cytometry, and functional neutralization assays, ensuring reliability across research and preclinical applications.

Creative Biolabs' N. gonorrhoeae LOS specific Neutra™ antibody products empower researchers and clinicians to address the dual challenges of gonococcal virulence and antibiotic resistance. With rigorously validated specificity and functional relevance, these tools accelerate therapeutic discovery and diagnostic innovation.

Contact our team today to discuss your project requirements and explore how our antibodies can advance your work against N. gonorrhoeae.

REFERENCE

• Gulati, Sunita, et al. "Targeting lipooligosaccharide (LOS) for a gonococcal vaccine." Frontiers in immunology 10 (2019): 321. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2019.00321